Illumina, Inc. (ILMN) AI Stock Analysis

Illumina, Inc. specializes in providing advanced sequencing and array-based solutions for genetic and genomic analysis across diverse sectors. Founded in 1998 and headquartered in San Diego, California, the company supplies instruments, consumables, genotyping and sequencing services, instrument service contracts, and collaborative development agreements. Its technologies serve research and clinical applications in life sciences, oncology, reproductive health, and agriculture, including cancer detection testing services. Illumina caters to genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical firms, biotechnology companies, commercial diagnostic labs, and consumer genomics enterprises through direct sales and life-science distributors across North America, Europe, Latin America, and the Asia-Pacific region.

Illumina's annual revenue was $4.34B in FY2025, compared to $4.53B in FY2021, reflecting a 5-year revenue CAGR of 6.0%. After reporting net income of -$4.40B in FY2022, -$1.16B in FY2023, and -$1.22B in FY2024, the company posted net income of $850.0M in FY2025 with an operating margin of 19.9% and a gross margin of 66.7%. For the trailing twelve months ending June 30, 2026, revenue was $4.49B with a profit margin of 18.3%. In the latest quarter, quarterly revenue grew 9.4% year-over-year, while quarterly earnings declined 9.4%.

As of June 30, 2026, Illumina held $1.17B in cash and short-term investments and $2.53B in total debt, resulting in net debt of $1.36B. Total assets stood at $6.65B and shareholders' equity was $2.84B, supporting a current ratio of 1.80 and a debt-to-equity ratio of 0.89. In FY2025, operating cash flow reached $1.08B and free cash flow was $931.0M. Capital allocation in FY2025 included $148.0M for capital expenditures and $742.0M for share buybacks, with its 5-year share count down 2.5%.

Illumina trades at a trailing P/E of 49.0x and a forward P/E of 40.3x, higher than the median of its S&P 500 Healthcare peers at 27.2x and 16.5x, respectively. Its enterprise value of $38.73B translates to an EV/EBITDA multiple of 28.0x, above the peer group median of 15.0x. The company has a price-to-sales multiple of 8.8x compared to the peer median of 3.4x. Over the past year, Illumina's 173.7% return outpaced the S&P 500 index return of 16.8%, though its 5-year return of -34.2% lagged the index's 83.0% gain.

Consensus ratings include 7 Strong Buy, 4 Buy, 6 Hold, 2 Sell, and 2 Strong Sell recommendations. The mean price target is $241.05, which is 8.2% below the last close of $262.54. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $4.62B and EPS of $5.36. For the next fiscal year, 21 analysts estimate revenue of $4.92B and EPS of $6.13. Illumina has beaten consensus EPS estimates in each of the last 4 quarters, with its next earnings report scheduled for October 29, 2026.

This page is an AI-written research summary of Illumina, Inc. (ILMN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ILMN income statement, ILMN balance sheet, ILMN key metrics, ILMN analyst forecast, ILMN chart. See the ILMN stock overview for the latest quote and news.